Latest Metformin Stories
A recent study found that early, prolonged treatment with the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome (PCOS) in adolescence.
Boehringer Ingelheim and Lilly today announced Phase III study results for linagliptin*, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately controlled on current therapy.
GRAND RAPIDS, Mich., June 29, 2011 /PRNewswire/ -- Delivering a healthy dose of good news to Midwest families, Meijer announced today that its free pre-natal vitamins prescription program has filled its 1,000,000th prescription, at a cost savings of nearly $14 million to Midwest families. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/meijer/50770/ (Photo: http://photos.prnewswire.com/prnh/20110629/MM22967 ) The announcement, made...
MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ -- ChemoCentryx, Inc.
In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMETÂ® (sitagliptin/metformin HCl) tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.
THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.
SAN DIEGO, June 25, 2011 /PRNewswire/ -- Novo Nordisk will present data from two extension studies at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) which show that VictozaÂ® (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies.
SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce results presented at a late-breaking poster session demonstrating linagliptin was as effective at lowering blood sugar as glimepiride, and with weight loss instead of weight gain (-1.5 kg with linagliptin versus +1.3 kg with glimepiride), a lower incidence of investigator-defined hypoglycemia (7.5 percent versus 36.1 percent; p<0.0001) and fewer cardiovascular (CV) events in...
SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood sugar is not adequately controlled.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.